WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research

Executive Summary: WY-14643 (Pirinixic Acid) is a potent and highly selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), with an IC₅₀ of 10.11 μM for human PPARα, enabling precise manipulation of lipid metabolism and inflammatory pathways in metabolic research (Bao et al., 2025). Aliphatic α-substitution increases its dual agonist activity on PPARα and PPARγ, expanding its utility in translational models (APExBIO). In vivo, it enhances insulin sensitivity, lowers plasma and hepatic triglycerides, and reduces visceral fat in diet-induced metabolic models without increasing body weight (APExBIO). WY-14643 exhibits anti-inflammatory effects by downregulating VCAM-1 expression and monocyte adhesion in endothelial cells. Its mechanism and application scope are supported by both preclinical and multiomics evidence.

Biological Rationale

PPARα is a ligand-activated nuclear receptor playing a central role in lipid metabolism, inflammation, and energy homeostasis. Activation of PPARα modulates the transcription of genes involved in fatty acid oxidation, transport, and peroxisome proliferation (Bao et al., 2025). Dysregulation of PPARα pathways is implicated in metabolic disorders, including type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD). WY-14643 is a research-grade, highly selective PPARα agonist that enables experimental manipulation of these pathways, providing insight into therapeutic targets and disease mechanisms. Its dual activity on PPARα/γ (via α-substitution) further broadens its use in models requiring nuanced modulation of the PPAR signaling axis.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds to the ligand-binding domain of PPARα with an IC₅₀ of 10.11 μM in human PPARα assays (APExBIO). Upon activation, PPARα heterodimerizes with RXR (retinoid X receptor) and binds to PPAR response elements (PPREs) in the promoter region of target genes. This leads to increased transcription of genes encoding enzymes involved in mitochondrial and peroxisomal β-oxidation, lipid transporters, and anti-inflammatory mediators. Aliphatic α-substitution of WY-14643 increases its potency as a dual PPARα/γ agonist, achieving EC₅₀ values in the low micromolar range (APExBIO). In endothelial cells, WY-14643 pretreatment (250 μM, 1 hour) downregulates TNF-α-induced VCAM-1 expression and reduces monocyte adhesion, demonstrating anti-inflammatory potential.

Evidence & Benchmarks

• WY-14643 activates human PPARα with an IC₅₀ of 10.11 μM (APExBIO A4305 datasheet, link).
• Aliphatic α-substitution increases dual PPARα/γ agonist activity to the low micromolar range (APExBIO, link).
• In high fat-fed rats, oral WY-14643 (3 mg/kg/day, 2 weeks) lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, and enhances insulin sensitivity (APExBIO, link).
• WY-14643 pretreatment (250 μM) in endothelial cells downregulates VCAM-1 expression and monocyte adhesion after TNF-α challenge (APExBIO, link).
• Linoleic acid upregulates TF expression through PPARα, as shown in tumor models, supporting the mechanistic role of PPARα agonists in modulating the tumor microenvironment (Bao et al., 2025).
• Multiomics profiling links PPARα signaling to tissue factor regulation and tumor progression in lung cancer subtypes, reinforcing the translational relevance of PPAR agonists (Bao et al., 2025).

For a comprehensive review of translational research leveraging WY-14643, see "WY-14643 (Pirinixic Acid): Mechanistic Leverage and Translational Insights" (which this article updates by integrating the latest multiomics and tumor microenvironment data). For practical guidance on experimental design, "WY-14643: Selective PPARα Agonist for Metabolic Research" offers protocol-focused insights, whereas this article emphasizes mechanistic rationale and recent benchmarking.

Applications, Limits & Misconceptions

WY-14643 is widely used in basic and translational research on metabolic disorders, including obesity, diabetes, and NAFLD. It is also employed to probe inflammation, endothelial function, and tumor microenvironment modulation. However, the compound is not approved for diagnostic or therapeutic use in humans and should not be used for clinical purposes. Its selectivity is high for PPARα, but at elevated concentrations or with chemical modifications, partial PPARγ agonism may occur. The anti-inflammatory effects are context-dependent and may not translate across all tissue types or disease models.

Common Pitfalls or Misconceptions

• WY-14643 is not a pan-PPAR agonist; its primary activity is on PPARα, with dual activity only upon specific α-substitution.
• It is not water soluble; dissolution requires DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic assistance).
• Long-term solution storage reduces potency; freshly prepared solutions are recommended.
• Research-use only: not suitable for diagnostic or clinical therapeutic applications.
• Response in tumor models may vary by cancer type; effects shown in pLELC models may not translate to all solid tumors (Bao et al., 2025).

Workflow Integration & Parameters

WY-14643 (A4305, supplied by APExBIO) is provided as a solid, stored at -20°C. For in vitro applications, dissolve in DMSO at concentrations up to 16.2 mg/mL; for ethanol, use ultrasonic assistance for up to 48.8 mg/mL. In cellular assays, effective concentrations typically range from 10 to 250 μM, while in vivo dosing in rodent models is commonly 3 mg/kg/day orally for 2 weeks. Solutions should be prepared fresh for each experiment. All use must adhere strictly to research-only protocols.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a best-in-class tool for dissecting PPARα-driven metabolic and inflammatory pathways. Its potency, selectivity, and validated performance in cellular and animal models make it indispensable for metabolic disorder and immunometabolic research. The evolving understanding of PPARα signaling—bolstered by recent multiomics data—highlights the translational relevance of WY-14643 in both metabolic and tumor microenvironment studies (Bao et al., 2025). For researchers seeking robust, reproducible modulation of PPAR signaling, the A4305 kit from APExBIO offers standardized quality and comprehensive documentation.